DFDA

Bevacizumab + Pemetrexed + Cisplatin

Treatment for Mesothelioma

Typical Dosage: Bevacizumab 15mg/kg Q3W + Pemetrexed 500mg/m² Q3W + Cisplatin 75mg/m² Q3W

Effectiveness
65%
Safety Score
20%
Clinical Trials
3
Participants
3K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Bevacizumab 15mg/kg Q3W + Pemetrexed 500mg/m² Q3W + Cisplatin 75mg/m² Q3W
Time to Effect
6-9 weeks (initial response)
Treatment Duration
6 cycles + maintenance Bevacizumab
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$15,000
Side Effect Mgmt:$12,000
Total Annual:$107,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$175,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$194,545
Cost per Remission
$2,140,000
Comparison vs Pemetrexed + Cisplatin
Cost Difference
+$87,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Bevacizumab + Pemetrexed + Cisplatin Outcomes

for Mesothelioma

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Remission Rate
+5%
Common Side Effects
Neutropenia
+35%
Fatigue
+45%
Nausea/Vomiting
+30%
Hypertension
+25%
Proteinuria
+15%
Hemorrhage
+12%
GI perforation
+3%

Sources:

nih.gov
ascopubs.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Bevacizumab + Pemetrexed + Cisplatin in Mesothelioma

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

NCT06543069RECRUITINGPHASE2
View Study
28 participants
INTERVENTIONAL
Beijing, China
Started: Jan 31, 2024
Completed Clinical Trials
2 completed trials for Bevacizumab + Pemetrexed + Cisplatin in Mesothelioma

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

NCT00295503COMPLETEDPHASE2
View Study
53 participants
INTERVENTIONAL
Dallas, United States
Started: Feb 1, 2006

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

NCT00651456COMPLETEDPHASE2, PHASE3
View Study
448 participants
INTERVENTIONAL
Aix-en-Provence, France +80 more
Started: Feb 1, 2008